相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
Georgina V. Long et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions
Klaus J. Busam et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
J. S. Wilmott et al.
BRITISH JOURNAL OF CANCER (2013)
E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression
J. Lade-Keller et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Detection of BRAF p.V600E Mutations in Melanomas Comparison of Four Methods Argues for Sequential Use of Immunohistochemistry and Pyrosequencing
Emeline Colomba et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
I. V. Fedorenko et al.
ONCOGENE (2013)
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
David Capper et al.
ACTA NEUROPATHOLOGICA (2012)
Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
Stephanie Moreau et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
Antonella De Luca et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Janice M. Mehnert et al.
CURRENT ONCOLOGY REPORTS (2012)
From genes to drugs: targeted strategies for melanoma
Keith T. Flaherty et al.
NATURE REVIEWS CANCER (2012)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
Gastrointestinal Stromal Tumor Markers in Cutaneous Melanomas
Raul S. Gonzalez et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong et al.
CLINICAL CANCER RESEARCH (2011)
New drugs in melanoma: It's a whole new world
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value
Junna Oba et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Bianca Devitt et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
C-KIT Signaling Depends on Microphthalmia-Associated Transcription Factor for Effects on Cell Proliferation
Bengt Phung et al.
PLOS ONE (2011)
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Nageatte Ibrahim et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2009)
Genome-wide screen of promoter methylation identifies novel markers in melanoma
Yasuo Koga et al.
GENOME RESEARCH (2009)
Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas
Bianca Costa Soares de Sa et al.
MELANOMA RESEARCH (2009)
Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
Braslav Jovanovic et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma
Roland Houben et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
How to make a melanoma: what do we know of the primary clonal events?
Dorothy C. Bennett
PIGMENT CELL & MELANOMA RESEARCH (2008)
B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
Selma Ugurel et al.
PLOS ONE (2007)
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose et al.
MELANOMA RESEARCH (2006)
p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
D Mihic-Probst et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
L Zhuang et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
R Nenutil et al.
JOURNAL OF PATHOLOGY (2005)
Expression of activated Akt and PTEN in malignant melanomas - Relationship with clinical outcome
A Slipicevic et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients
F Janku et al.
MELANOMA RESEARCH (2005)
PTEN expression in melanoma: Relationship with patient survival, Bcl-2 expression, and proliferation
M Mikhail et al.
CLINICAL CANCER RESEARCH (2005)
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A
AE Loercher et al.
JOURNAL OF CELL BIOLOGY (2005)
Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions
D Stefanou et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2004)
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas
M Shinozaki et al.
CLINICAL CANCER RESEARCH (2004)
Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma
A Potti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Progression in cutaneous malignant melanoma is associated with distinct expression profiles - A tissue microarray-based study
SR Alonso et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
p53-related pathways and the molecular pathogenesis of melanoma
MR Hussein et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma
H Tsao et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma
A Baldi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2001)
The multiple roles of PTEN in tumor suppression
A Di Cristofano et al.
CELL (2000)
分享论文
